Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion type Assertion NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_head.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion description "[In recent years, the development of GCGR antisense oligonucleotides and small molecular weight GCGR antagonists have been pursued as possible therapeutic agents to target glucagon action as a treatment for Type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_provenance.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion evidence source_evidence_literature NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_provenance.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion SIO_000772 15948676 NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_provenance.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion wasDerivedFrom befree-20150227 NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_provenance.
- NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_assertion wasGeneratedBy ECO_0000203 NP420446.RANGFGCPBPmsX_b4xY2F3PbwKizF4iVV2_Fhl13anvZXE130_provenance.